I like Paul's answer to the Top-Line data question....I think it bodes well for the long term assuming BETonMACE  succeeds on the primary endpoint.  While there are likely a myriad of possibilities in the way things can play out...if all goes well I can envision something along these lines, all predicated on Top-Line succeeding.

-Announcement that BETonMACE succeeded in meeting the primary end point.

-Secondary offering perhaps in tandem with a Nasdaq listing raising sufficient capital to commence CKD and Fabry's trials.

-Release of data on CKD and Alzheimer's perhaps together or separately...

-Filing of a NDA for Diabetics at high risk of CVD

-Further annoucements of additional data points with the potential to point the way to other indications...

-Design and implementation of further trials based on BETonMACE's full data set with an eye to expanding the label assuming initial NDA approval...

-Follow on compounds (the dream factory) begin to enter pre-clinical then clinical testing...

-Further secondary offerings intersprersed throughout the release of good news as Apabetalone's full potential becomes recognized.  

For me its been a 5+ year journey, for others much longer.....but thinking about the possibilities going forward has me thinking that RVX may very well end up being a core holding for me....and reading that the company is apparently not interested in hyping the results by tring to make a big 'all at once' splash is very encouraging imo.